Case study: becoming the first GMP-certified cell and gene therapy manufacturing facility in Thailand

Roughly 30,000 new cases of leukemia and lymphoma are detected in Thailand every year. Approximately 40% of these cases do not respond to traditional treatment such as chemotherapy. Patients with these unresponsive cancers can then turn to CAR-T cell therapy as a subsequent treatment option. However, there are several challenges associated with the production process for CAR-T cell therapies, including complexity, cost, and regulatory obstacles. Despite these challenges, Genepeutic Bio is able to provide services for CAR-T cell production and is the first GMP-certified manufacturing facility in Thailand to do so. This article explores how Genepeutic Bio is increasing the accessibility of CAR-T cell therapies to people in Southeast Asia through their production of an anti-CD19 CAR-T cell therapy.

Please enter your email to access content Read now